Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: traditional chemotherapy or biomarker-driven therapy.
Thomas W. Flaig, MD
Articles by Thomas W. Flaig, MD
Thomas Flaig, MD, discusses recent updates seen in the bladder cancer space and how they have led to changes to the NCCN guidelines.
Thomas Flaig, MD, discusses some of the updated and current NCCN guidelines for patients with bladder cancer.
Thomas W. Flaig, MD, discusses the most dramatic change in the treatment landscape for patients with advanced bladder cancer. Over the last several years, 5 checkpoint inhibitors have been approved in this space.
